JPMorgan lifts Merck price target to $165

JPMorgan has raised its price target for Merck from $150 to $165, according to a report from TipRanks. This adjustment reflects the firm's updated outlook on the pharmaceutical company's performance. The report emphasizes that the TipRanks Smart Score performance is based on backtested results, which means the results are derived from applying a model retroactively to historical data.

The backtested performance is not indicative of future actual results, and the report includes several disclaimers. These disclaimers highlight that the results reflect a strategy not historically offered to investors and do not represent returns any investor actually attained. The backtested results are calculated by retroactively applying a model based on historical data and assumptions that may not be testable and are subject to losses.

The report also notes that certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations or warranties are made regarding the reasonableness of these assumptions. The information is provided for illustrative purposes only, and backtested performance is developed with the benefit of hindsight, which has inherent limitations.

Backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. The report cautions that since trades have not actually been executed, results may have under- or over-compensated for the impact of certain market factors, such as lack of liquidity. Actual performance may differ significantly from backtested performance.